TechNavio today launched its report Global Breast Cancer Drugs Market 2011-2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said; ”The current trend witnessed by the Global Breast Cancer Drugs market is combination therapy being used to treat breast cancer. Many oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites in the body can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient’s body. The combination therapy is decided on depending on the size of the tumor and the risk of recurrence.”
According to the report, globally, there has been an increase in the number of women being diagnosed with breast cancer. The increase in the incidence of breast cancer is due to a variety of factors such as obesity, excessive drinking of alcohol, and lack of exercise. Thus, with the increase in the prevalence of breast cancer, the demand for breast cancer drugs is also increasing.
Further, the report also discusses that the key challenge being confronted by the Global Breast Cancer Drugs market is the presence of alternative treatments for breast cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit http://goo.gl/wDzf4
Follow us on Twitter @ Technavio